Is a complete GALT research report available?

No complete published report is available for Galectin Therapeutics Inc. (GALT) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Galectin Therapeutics Inc. (GALT)

NASDAQ: GALT · USD

$3.23

-0.26 (-7.5%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-31 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first GALT analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	212.7M
Net income (ttm)	-26.4M
EPS (ttm)	-$0.41
Shares out	65.9M
Volume	404,329
Beta	0.35

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -26.4M
EPS (ttm): -$0.41
Market cap: 212.7M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	27.4B	36.9x	5.7x	96.6%	+47.5%	-37.8%	Strong Buy
ARGX	argenx SE	53.8B	31.3x	10.1x	50.6%	+58.8%	+45.7%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All GALT indicators

Market & fundamental data

Available fields

174

Groups with data

Currency

USD

Showing 174 of 174 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001133416
Company name	Galectin Therapeutics Inc.
Country	United States
Country code	US
Cusip	363225202
Employees	9
Employees Change	-6%
Employees Change Percent	-40
Enterprise value	$342.6M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	US3632252025
Last refreshed	2026-07-31
Market cap	$212.7M
Market cap category	Micro-Cap
Price	$3.23
Price currency	USD
Sector	Healthcare
Sector PE	45.56
Sector PE Fwd	24.38
Sic	2834
Symbol	GALT
Website	https://galectintherapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-12.13%

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-26.4M
Net Income Growth Quarters	5%
Net Income Growth Years	1%
Profit Per Employee	$-2.9M
ROA	-80.4
Roa5y	-81.77
ROCE	-192.4
ROIC	-439.6

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	7.01%
Cagr15y	-4.23%
Cagr1y	-2.12%
Cagr20y	-6.92%
Cagr3y	29.41%
Cagr5y	4.28%
EPS Growth Quarters	5
EPS Growth Years	1
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$15.8M
Cash	$14.1M
Current Assets	$15.7M
Current Liabilities	$7.3M
Debt	$138.7M
Equity	$-130.2M
Interest Coverage	-2.15
Liabilities	$146M
Long Term Assets	$68,000
Long Term Liabilities	$138.7M
Net Cash	$-124.6M
Net Cash By Market Cap	$-57.15
Tangible Book Value	$-132.4M
Tangible Book Value Per Share	$-2.01
WACC	5.46

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	2.15
Net Working Capital	$-5.7M
Quick ratio	1.93
Working Capital	$8.4M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-3.09%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	96.95%
1Y total return	-2.12%
200-day SMA	3.67
3Y total return	116.78%
50-day SMA	3.4
50-day SMA vs 200-day SMA	50under200
5Y total return	23.28%
All Time High	38.28
All Time High Change	-91.56%
All Time High Date	2003-09-12
All Time Low	0.3
All Time Low Change	976.67%
All Time Low Date	2009-01-12
ATR	0.39
Beta	0.35
Beta1y	-1.31
Beta2y	0.52
Ch YTD	-22.36
High	3.6
High52	7.13
High52 Date	2025-12-17
High52ch	-54.7%
Low	3.21
Low52	2.03
Low52 Date	2026-05-07
Low52ch	59.51%
Ma50ch	-4.92%
Premarket Change Percent	3.15
Premarket Price	$3.6
Premarket Volume	799
Price vs 200-day SMA	-11.87%
RSI	40.48
RSI Monthly	51.27
RSI Weekly	49.96
Sharpe ratio	0.41x
Sortino ratio	0.67
Total Return	-3.09%
Tr YTD	-22.36
Tr15y	-47.73%
Tr1m	-35.01%
Tr1w	-6.38%
Tr3m	43.56%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Earnings EPS Estimate	$-0.09
Operating Income	$-16.3M

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	47,186,886%
Float Percent	71.65%
Net Borrowing	21,000,000
Shares Insiders	19.82%
Shares Institutions	22.04%
Shares Out	65,856,898
Shares Qo Q	1.6%
Shares Yo Y	3.09%
Short Float	18%
Short Ratio	6.75
Short Shares	12.9

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted OCF	-21,929,000
Average Volume	552,089.85x
Bv Per Share	-2.01
Ch10y	96.95
Ch15y	-47.73
Ch1m	-35.01
Ch1w	-6.38
Ch1y	-2.12
Ch20y	-76.18
Ch3m	43.56
Ch3y	116.8
Ch5y	23.28
Ch6m	10.24
Change	-7.45%
Change From Open	-7.98
Close	3.49
Days Gap	0.57
Depreciation Amortization	55,000
Dollar Volume	1,305,982.7
Earnings Date	2026-08-14
Earnings Time	bmo
EBIT	$-16.3M
EBITDA	$-16.2M
EPS	$-0.41
F Score	2
Financing CF	26,732,000
Fiscal Year End	December
Founded	2,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-15
Last Report Date	2026-03-31
Last Split Date	2012-03-23
Last Split Type	Reverse
Last10k Filing Date	2026-03-31
Ma150	3.04
Ma150ch	6.15%
Ma20	4.08
Ma20ch	-20.78%
Net CF	6,680,000
Next Earnings Date	2026-08-13
Open	3.51
Optionable	Yes
Position In Range	4.39
Post Close	3.23
Postmarket Change Percent	1.24
Postmarket Price	$3.27
Pre Close	3.49
Price Date	2026-07-30
Relative Volume	0.73x
Share Based Comp	1,877,000
Tr20y	-76.18%
Tr6m	10.24%
Us State	Georgia
Volume	404,329

Galectin Therapeutics Inc. (GALT)

Coverage state: Market snapshot only — no published research

Generate the first GALT analysis

Price

Financial snapshot

Fair-value bridge

Latest news · GALT

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All GALT indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on GALT

Frequently asked questions